Scilex (NASDAQ:SCLX) Downgraded to "Strong Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Scilex (SCLX) from "hold" to "strong sell", while Weiss Ratings reaffirmed a "sell (d-)", leaving the MarketBeat consensus rating as Sell.
• Scilex reported a major quarterly miss, with EPS of ($4.60) vs. a consensus of ($0.47) and revenue of $4.79M versus $12.10M expected, highlighting weak near-term fundamentals.
• The stock trades around $10.58 with a market cap near $89.8M, a 12‑month range of $3.92–$34.27, and roughly 69.7% institutional ownership amid recent stake changes by firms like Goldman Sachs and Norges Bank.

Scilex (NASDAQ:SCLX - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "strong sell" rating in a research report issued on Saturday.

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Scilex in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of "Sell".

Scilex Stock Up 0.6%

SCLX opened at $10.58 on Friday. The firm has a 50 day moving average price of $7.55 and a 200-day moving average price of $11.97. Scilex has a twelve month low of $3.92 and a twelve month high of $34.27. The stock has a market capitalization of $89.82 million, a price-to-earnings ratio of -0.29 and a beta of 1.77.

Scilex (NASDAQ:SCLX - Get Free Report) last released its quarterly earnings data on Friday, April 10th. The company reported ($4.60) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($4.13). The firm had revenue of $4.79 million for the quarter, compared to analysts' expectations of $12.10 million.

Institutional Trading of Scilex

A number of institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. lifted its stake in Scilex by 31.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 136,352 shares of the company's stock valued at $34,000 after acquiring an additional 32,449 shares during the period. Norges Bank acquired a new stake in Scilex during the 2nd quarter valued at approximately $80,000. BNP Paribas Financial Markets lifted its stake in Scilex by 189.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,430 shares of the company's stock valued at $146,000 after acquiring an additional 4,864 shares during the period. OMERS ADMINISTRATION Corp acquired a new stake in Scilex during the 4th quarter valued at approximately $150,000. Finally, XTX Topco Ltd acquired a new stake in Scilex during the 4th quarter valued at approximately $249,000. 69.67% of the stock is currently owned by institutional investors and hedge funds.

Scilex Company Profile

Scilex Holdings, Inc NASDAQ: SCLX is a specialty pharmaceutical company focused on non-opioid treatments for chronic pain. The firm's principal commercial product, ZTlido®, is a lidocaine topical system approved by the U.S. Food and Drug Administration for the management of post-herpetic neuralgia and certain peripheral neuropathic pain conditions. By leveraging a proprietary drug delivery platform, Scilex aims to improve patient comfort and safety compared to traditional oral analgesics.

In addition to marketing ZTlido® in the United States, Scilex is advancing other pain management assets through clinical development and regulatory pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.